[Update 2021: COVID-19 from the Perspective of Haematology and Haemostaseology].
Update 2021: COVID-19 aus Sicht der Hämatologie und Hämostaseologie.
Journal
Deutsche medizinische Wochenschrift (1946)
ISSN: 1439-4413
Titre abrégé: Dtsch Med Wochenschr
Pays: Germany
ID NLM: 0006723
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
entrez:
13
7
2021
pubmed:
14
7
2021
medline:
21
7
2021
Statut:
ppublish
Résumé
Infection with SARS-CoV-2 has a profound influence on the hematopoetic system that mediates clinical symptoms and mortality. Several studies have shown that treatment of the cytokine storm (CRS) with anti-inflammatory drugs like dexamethasone and tocilizumab can significantly improve survival. Systematic reviews confirm the safety of convalescent plasma administration and offer initial indications of its effectiveness in certain groups. COVID-associated coagulopathy (CAC) and vaccine-induced immune thrombotic thrombocytopenia (VITT) represent severe infection- or vaccination associated complications that require a specific diagnostic and therapeutic workup.
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
899-903Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
Marion Subklewe: Research Support: Amgen, BMS/Celgene, Gilead, Miltenyi, MorphoSys, Novartis, Roche, Seattle Genetics; Advisory Boards: Amgen, BMS/Celgene, Gilead, Janssen, Novartis, Pfizer, Seattle Genetics; Speaker’s Bureau: Amgen, BMS/Celgene, Gilead, Novartis, Pfizer, Takeda.Andreas Humpe: Leitung von Kongressveranstaltungen für die Fa. Sanofi-Aventis gegen Honorar, Vortrag für die Fa. Cerus gegen Honorar.